Also, in a phase 1 trial of advanced gastric or colorectal cancer patients treated with Regorafenib (Anti-VEGF) plus anti-PD-1, colorectal cancer patients with lung metastases had a higher response rate (ORR, 66.7%) particularly compared to patients with liver metastases (ORR, 40%) (79). The gene discussed is PDCD1; the disease is colorectal cancer.